The results of the phase 2 study suggest that participants who had received the treatment had better scores in the visual memory recognition and inhibition tasks, and improvement in adaptive behavior than those in the control group. Though not a cure, this is the first time that a treatment has shown some effectiveness in this syndrome, and it opens the door to new research geared towards treating what was believed to be orphan of treatment.